bioAffinity Technologies, Inc. shared a patient case study on July 9, 2025, where its CyPath® Lung test detected Stage 1A lung cancer in a high-risk patient with inconclusive imaging. The patient, with a 50 pack-year smoking history, had a suspicious nodule on a CT scan that did not provide a definitive diagnosis.
In situations where imaging was inconclusive and other diagnostics were contraindicated, CyPath® Lung provided a 'likely cancer' result. This actionable information prompted a biopsy, which subsequently confirmed a diagnosis of Stage 1A adenocarcinoma.
This case further validates CyPath® Lung's capability to offer diagnostic clarity in complex clinical scenarios, enabling earlier intervention. Early detection of lung cancer, particularly at Stage 1A, significantly improves the chances for curative treatment and better patient outcomes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.